ALK-Abelló A/S (AKABY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ALK-Abelló A/S (AKABY) trades at $90.00 with AI Score 54/100 (Grade B). ALK-Abelló A/S is a global allergy solutions company specializing in allergy immunotherapy products. Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for AKABY: AKABY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AKABY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
AKABY: 4/6 perspectives are bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →ALK-Abelló A/S (AKABY) Healthcare & Pipeline Overview
ALK-Abelló A/S, founded in 1923, is a global allergy solutions company focused on developing and marketing allergy immunotherapy products. With a presence in Europe, North America, and internationally, the company offers a range of treatments, including injections, sublingual drops, and adrenaline auto-injectors, addressing conditions like allergic rhinitis and allergic asthma.
What Is the Investment Thesis for AKABY?
ALK-Abelló A/S presents a notable research candidate within the allergy solutions market. The company's strong financial performance, indicated by a profit margin of 19.0% and a gross margin of 67.1%, highlights its operational efficiency. With a P/E ratio of 39.43 and a dividend yield of 0.75%, AKABY offers a blend of growth and income potential. The company's beta of 0.43 suggests lower volatility compared to the broader market. Growth catalysts include the expansion of its product portfolio and geographic reach. However, potential risks include competition from other biotechnology companies and regulatory hurdles. The company's continued focus on research and development, coupled with its established market presence, positions it for sustained growth in the allergy solutions sector.
Based on FMP financials and quantitative analysis
AKABY Key Highlights
- ALK-Abelló A/S boasts a strong profit margin of 19.0%, showcasing efficient operations and profitability within the biotechnology sector.
- The company's gross margin of 67.1% indicates effective cost management and pricing strategies in its allergy solutions business.
- With a P/E ratio of 39.43, ALK-Abelló A/S is trading at a premium, reflecting investor confidence in its growth prospects.
- ALK-Abelló A/S offers a dividend yield of 0.75%, providing a modest income stream for investors.
- The company's low beta of 0.43 suggests that the stock is less volatile than the overall market, making it a potentially stable investment.
Who Are AKABY's Competitors?
AKABY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABCZF Abcam plc | $22.25 | +0.68% | $5.12B | 46 |
| ALPN Alpine Immune Sciences, Inc. | $64.97 | +0.02% | $4.46B | 57 |
| ARNA Arena Pharmaceuticals, Inc. | $99.99 | +0.00% | 53 | |
| CCXI ChemoCentryx, Inc. | $17.87 | -6.44% | $748.75M | 67 |
| GBT Global Blood Therapeutics, Inc. | $68.49 | +0.01% | 46 | |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AKABY's Key Strengths?
- Strong product portfolio of allergy immunotherapy products.
- Established presence in Europe and North America.
- High gross margin of 67.1%.
- Experienced management team.
What Are AKABY's Weaknesses?
- Dependence on a limited number of key products.
- Exposure to regulatory risks and pricing pressures.
- Limited presence in emerging markets.
- Competition from larger pharmaceutical companies.
What Could Drive AKABY Stock Higher?
- Potential regulatory approvals for new allergy immunotherapy products in key markets (2026-2027).
- Expansion of the company's digital health solutions to improve patient engagement.
- Strategic partnerships with healthcare providers to increase market access.
- Publication of clinical trial results for novel allergy therapies (2026).
- Increasing awareness of anaphylaxis and the importance of adrenaline auto-injectors.
What Are the Key Risks for AKABY?
- Competition from generic allergy medications could erode market share.
- Changes in regulatory requirements could increase compliance costs.
- Economic downturns could affect healthcare spending and demand for allergy treatments.
- Product liability claims related to allergy medications or auto-injectors.
- Dependence on key products exposes the company to revenue concentration risk.
What Are the Growth Opportunities for AKABY?
- Expansion into Emerging Markets: ALK-Abelló A/S has the opportunity to expand its presence in emerging markets, such as Asia and Latin America, where the prevalence of allergies is increasing. By establishing partnerships with local distributors and healthcare providers, the company can introduce its allergy immunotherapy products to a broader patient base. The global allergy market is estimated to reach $25 billion by 2028, providing a significant growth opportunity for ALK-Abelló. Timeline: 2026-2030.
- Development of Novel Allergy Therapies: Investing in research and development to create novel allergy therapies, such as biologics and gene therapies, can provide ALK-Abelló A/S with a competitive edge. These advanced therapies have the potential to offer more effective and long-lasting relief for allergy sufferers. The market for biologic therapies is projected to grow at a CAGR of 12% over the next five years. Timeline: 2026-2032.
- Increased Focus on Digital Health Solutions: ALK-Abelló A/S can leverage digital health technologies, such as mobile apps and telehealth platforms, to improve patient engagement and adherence to allergy immunotherapy treatment. These solutions can provide patients with personalized support, education, and monitoring, leading to better outcomes. The digital health market is expected to reach $660 billion by 2027. Timeline: 2026-2029.
- Strategic Acquisitions and Partnerships: Pursuing strategic acquisitions and partnerships with other companies in the allergy and immunology space can expand ALK-Abelló A/S's product portfolio and market reach. This can also provide access to new technologies and expertise. The company could explore collaborations with diagnostic companies to improve allergy testing and diagnosis. Timeline: Ongoing.
- Expansion of Adrenaline Auto-Injector Market: ALK-Abelló A/S can focus on expanding its market share in the adrenaline auto-injector market. This involves increasing awareness of anaphylaxis and the importance of having access to life-saving treatment. The company can also develop innovative auto-injector devices that are easier to use and more convenient for patients. The global adrenaline auto-injector market is projected to reach $5 billion by 2027. Timeline: 2026-2028.
What Opportunities Does AKABY Have?
- Expansion into emerging markets.
- Development of novel allergy therapies.
- Increased focus on digital health solutions.
- Strategic acquisitions and partnerships.
What Threats Does AKABY Face?
- Competition from generic allergy medications.
- Changes in regulatory requirements.
- Economic downturns affecting healthcare spending.
- Product liability claims.
What Are AKABY's Competitive Advantages?
- Proprietary allergy immunotherapy formulations.
- Established brand reputation and market presence.
- Extensive research and development capabilities.
- Global distribution network.
What Does AKABY Do?
ALK-Abelló A/S, established in 1923 and headquartered in Hørsholm, Denmark, is a pioneering allergy solutions company dedicated to improving the lives of individuals suffering from allergies. The company develops, manufactures, and markets a comprehensive range of allergy immunotherapy products designed to treat various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. Its product portfolio includes injections, sublingual drops, and tablets, providing patients with diverse treatment options tailored to their specific needs. ALK-Abelló's key products include GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX, all targeting allergic rhinitis. ACARIZAX is specifically designed for treating allergic rhinitis and allergic asthma. In addition to allergy immunotherapy, ALK-Abelló also provides adrenaline auto-injectors for managing severe allergic reactions, ensuring patients have access to life-saving treatments during emergencies. The company's commitment to innovation extends to manufacturing products used in the diagnosis of allergies, enabling accurate and timely identification of allergens. With a global presence spanning Europe, North America, and other international markets, ALK-Abelló has established itself as a leader in the allergy solutions industry. The company's extensive research and development efforts, coupled with its focus on patient-centric solutions, have solidified its position as a trusted provider of allergy treatments worldwide. As of 2026, ALK-Abelló continues to expand its product offerings and geographic reach, striving to meet the evolving needs of allergy sufferers globally.
What Products and Services Does AKABY Offer?
- Develops and markets allergy immunotherapy products.
- Offers treatments for house dust mite, grass, tree, ragweed, and Japanese cedar allergies.
- Provides allergy solutions in the form of injections, sublingual drops, and tablets.
- Manufactures adrenaline auto-injectors for severe allergic reactions.
- Produces products used in the diagnosis of allergies.
- Offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, ITULAZAX, and ACARIZAX.
How Does AKABY Make Money?
- Develops and manufactures allergy immunotherapy products.
- Markets and sells products through a global distribution network.
- Generates revenue through product sales to healthcare providers and patients.
- Invests in research and development to create new and improved allergy treatments.
What Industry Does AKABY Operate In?
ALK-Abelló A/S operates within the biotechnology industry, specifically focusing on allergy solutions. The market for allergy immunotherapy is growing, driven by increasing prevalence of allergies worldwide. The competitive landscape includes companies like ABCZF (Allergy Therapeutics PLC), ALPN (Alpine Immune Sciences Inc), ARNA (Arena Pharmaceuticals), CCXI (ChemoCentryx Inc), and GBT (Global Blood Therapeutics Inc), each with their own unique approaches to allergy treatment. ALK-Abelló's established presence in Europe and North America positions it well to capitalize on this growth.
Who Are AKABY's Key Customers?
- Healthcare providers (allergists, immunologists, general practitioners)
- Patients suffering from allergies
- Hospitals and clinics
- Pharmacies
Company Profile
ALK-Abelló A/S operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Horsholm, DK. The company is led by CEO Carsten Hellmann. AKABY has traded publicly since 2013.
How ALK-Abelló A/S Is Valued
Relative to its peer group, AKABY's quantitative score of 54/100 is roughly in line with the peer average of 54/100.
ROE 20%Key Financial Metrics
Return on equity for ALK-Abelló A/S stands at 20.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 13.8%, showing how much profit it generates from its asset base. AKABY trades at a trailing price-to-earnings ratio of 46.39, above the Healthcare sector average of ~23x. Its free cash flow yield is 3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.25 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.2%, the inverse of the P/E and a quick read on earnings relative to price.
AKABY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Strong product portfolio of allergy immunotherapy products.
- Established presence in Europe and North America.
- High gross margin of 67.1%.
- Experienced management team.
Bear Case
- Dependence on a limited number of key products.
- Exposure to regulatory risks and pricing pressures.
- Limited presence in emerging markets.
- Competition from larger pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
AKABY Latest News
No recent news available for AKABY.
AKABY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AKABY.
Price Targets
Wall Street price target analysis for AKABY.
AKABY MoonshotScore
What does this score mean?
The MoonshotScore rates AKABY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Carsten Hellmann
CEO
Carsten Hellmann serves as the CEO of ALK-Abelló A/S. His professional background includes extensive experience in the pharmaceutical and healthcare industries. Prior to joining ALK-Abelló, he held various leadership positions at major pharmaceutical companies, focusing on commercial operations, strategic planning, and business development. He brings a wealth of knowledge in global market expansion and product innovation to his role at ALK-Abelló.
Track Record: Under Carsten Hellmann's leadership, ALK-Abelló A/S has focused on expanding its global presence and strengthening its product portfolio. Key achievements include the successful launch of new allergy immunotherapy products and the implementation of digital health solutions to improve patient engagement. His strategic decisions have contributed to the company's revenue growth and profitability.
AKABY OTC Market Information
The OTC Other tier represents the lowest tier of over-the-counter (OTC) stocks. Companies in this tier often do not meet the minimum financial standards required for listing on major exchanges like the NYSE or NASDAQ. These companies may have limited operating history, be thinly traded, or have regulatory issues. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to listed companies. Investors should exercise extreme caution and conduct thorough due diligence before investing in these securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher volatility compared to listed stocks.
- Risk of delisting or suspension of trading.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements (if available).
- Assess the company's business model and competitive landscape.
- Research the management team and their track record.
- Evaluate the company's legal and regulatory compliance.
- Monitor trading volume and price activity.
- Understand the risks associated with OTC investing.
- Company has been in operation since 1923.
- Global presence in Europe, North America, and internationally.
- Offers a range of allergy immunotherapy products.
- Employs over 2500 people.
- Has a CEO with experience in the pharmaceutical industry.
Common Questions About AKABY (Healthcare)
What does ALK-Abelló A/S do?
ALK-Abelló A/S is a global allergy solutions company that develops, manufactures, and markets allergy immunotherapy products. The company offers a range of treatments for various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. These treatments are available in the form of injections, sublingual drops, and tablets. Additionally, ALK-Abelló provides adrenaline auto-injectors for managing severe allergic reactions, solidifying its position as a comprehensive allergy solutions provider.
What do analysts say about AKABY stock?
Analyst coverage of AKABY stock is limited due to its OTC listing. Key valuation metrics include a P/E ratio of 39.43, a profit margin of 19.0%, and a gross margin of 67.1%. Growth considerations include the company's expansion into emerging markets and its investment in novel allergy therapies. However, potential risks include competition from generic medications and regulatory hurdles. Investors should conduct their own research and consider their risk tolerance before investing.
What are the main risks for AKABY?
The main risks for ALK-Abelló A/S include competition from generic allergy medications, which could erode market share and pricing power. Regulatory changes and compliance costs pose another risk, particularly in the highly regulated pharmaceutical industry. Economic downturns could also affect healthcare spending and demand for allergy treatments. Furthermore, product liability claims related to allergy medications or auto-injectors could negatively impact the company's financial performance and reputation.
What are the key factors to evaluate for AKABY?
ALK-Abelló A/S (AKABY) holds an AI score of 54/100 (moderate). Not financial advice.
How frequently does AKABY data refresh on this page?
AKABY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven AKABY's recent stock price performance?
ALK-Abelló A/S (AKABY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong product portfolio of allergy immunotherapy products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AKABY overvalued or undervalued right now?
Valuing ALK-Abelló A/S (AKABY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying AKABY?
Before investing in ALK-Abelló A/S (AKABY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be less reliable than exchange-listed data.
- Analyst coverage may be limited due to OTC listing.